Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma

被引：34

作者：

Dhakras, Purabi ^{[1
]}

Uboha, Nataliya ^{[2
,3
,4
]}

Horner, Vanessa ^{[1
,5
]}

Reinig, Erica ^{[1
]}

Matkowskyj, Kristina A. ^{[1
,3
,4
]}

机构：

[1] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA

[2] Univ Wisconsin, Dept Med, Div Hematol Med Oncol & Palliat Care, Madison, WI USA

[3] UW Carbone Canc Ctr, Madison, WI USA

[4] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA

[5] Wisconsin State Lab Hyg, Madison, WI USA

来源：

TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY | 2020年 / 5卷

关键词：

Human epidermal growth factor receptor 2 (HER2); microsatellite instability (MSI); program death-ligand 1 (PD-L1); DNA MISMATCH REPAIR; SHORT-TERM PROGNOSIS; CELL LUNG-CANCER; MICROSATELLITE INSTABILITY; GENE AMPLIFICATION; FAMILIAL PREDISPOSITION; INTERNATIONAL CRITERIA; INSTITUTE WORKSHOP; PD-L1; EXPRESSION; C-ERBB-2; PROTEIN;

D O I：

10.21037/tgh.2020.01.08

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Esophageal and gastric adenocarcinomas are frequently diagnosed at an advanced stage and have a dismal prognosis. Even in patients with potentially curative cancer, nearly 50% will develop recurrent disease despite aggressive treatments. A number of biomarkers currently guide treatment decisions for patients with esophageal and gastric adenocarcinoma and include human epidermal growth factor receptor 2 (HER2) amplification, mismatch repair deficiency/microsatellite instability (dMMR/MSI-H) and program death-ligand 1 (PD-L1) expression. This review will focus on the function, testing and FDA-approved targeted therapies for HER2, dMMR/MSI-H and PD-L1. In addition, a number of novel targets in esophageal and gastric cancer are being studied in clinical trials. Neurotrophic-tropomyosin receptor kinase (NTRK), claudin-18 (CLDN18)/Rho GTPase activating protein 26 (ARHGAP26) gene fusion, fibroblast growth factor receptor (FGFR), lymphocyte-activation gene 3 (LAG3) and T cell immunoglobulin and mucin-domain containing-3 (TIM3) will be briefly reviewed. Despite several biomarkers used in the selection of treatment therapies, treatment outcomes remain poor. Future research efforts will focus on the identification of new biomarkers, moving existing biomarkers into earlier lines of therapy, and evaluating new combinations of existing biomarkers and therapies.

引用

页数：12

共 78 条

[1] A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker [J].

Aguiar, Pedro N., Jr. ;

Santoro, Ilka Lopes ;

Tadokoro, Hakaru ;

Lopes, Gilberto de Lima ;

Filardi, Bruno Andraus ;

Oliveira, Pedro ;

Castelo-Branco, Pedro ;

Mountzios, Giannis ;

de Mello, Ramon Andrade .

IMMUNOTHERAPY, 2016, 8 (09) :1011-1019

[2] The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis [J].

Aguiar, Pedro N., Jr. ;

Santoro, Ilka Lopes ;

Tadokoro, Hakaru ;

Lopes, Gilberto de Lima ;

Filardi, Bruno Andraus ;

Oliveira, Pedro ;

Mountzios, Giannis ;

de Mello, Ramon Andrade .

IMMUNOTHERAPY, 2016, 8 (04) :479-488

[3]

Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO

[4]

2-J

[5] Development of a fluorescent multiplex assay for detection of MSI-high tumors [J].

Bacher, JW ;

Flanagan, LA ;

Smalley, RL ;

Nassif, NA ;

Burgart, LJ ;

Halberg, RB ;

Megid, WMA ;

Thibodeau, SN .

DISEASE MARKERS, 2004, 20 (4-5) :237-250

[6]

Bang YJ, 2010, LANCET, V376, P1302

[7] Advances in the Management of HER2-positive Advanced Gastric and Gastroesophageal Junction Cancer [J].

Bang, Yung-Jue .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2012, 46 (08) :637-648

[8] HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology [J].

Bartley, Angela N. ;

Washington, Mary Kay ;

Ventura, Christina B. ;

Ismaila, Nofisat ;

Colasacco, Carol ;

Benson, Al B., III ;

Carrato, Alfredo ;

Gulley, Margaret L. ;

Jain, Dhanpat ;

Kakar, Sanjay ;

Mackay, Helen J. ;

Streutker, Catherine ;

Tang, Laura ;

Troxell, Megan ;

Ajani, Jaffer A. .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (12) :1345-1363

[9] Comprehensive molecular characterization of gastric adenocarcinoma [J].

Bass, Adam J. ;

Thorsson, Vesteinn ;

Shmulevich, Ilya ;

Reynolds, Sheila M. ;

Miller, Michael ;

Bernard, Brady ;

Hinoue, Toshinori ;

Laird, Peter W. ;

Curtis, Christina ;

Shen, Hui ;

Weisenberger, Daniel J. ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Weinhold, Nils ;

Keiser, David P. ;

Bowlby, Reanne ;

Sipahimalani, Payal ;

Cherniack, Andrew D. ;

Getz, Gad ;

Liu, Yingchun ;

Noble, Michael S. ;

Pedamallu, Chandra ;

Sougnez, Carrie ;

Taylor-Weiner, Amaro ;

Akbani, Rehan ;

Lee, Ju-Seog ;

Liu, Wenbin ;

Mills, Gordon B. ;

Yang, Da ;

Zhang, Wei ;

Pantazi, Angeliki ;

Parfenov, Michael ;

Gulley, Margaret ;

Piazuelo, M. Blanca ;

Schneider, Barbara G. ;

Kim, Jihun ;

Boussioutas, Alex ;

Sheth, Margi ;

Demchok, John A. ;

Rabkin, Charles S. ;

Willis, Joseph E. ;

Ng, Sam ;

Garman, Katherine ;

Beer, David G. ;

Pennathur, Arjun ;

Raphael, Benjamin J. ;

Wu, Hsin-Ta ;

Odze, Robert ;

Kim, Hark K. ;

Bowen, Jay .

NATURE, 2014, 513 (7517) :202-209

[10] Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome [J].

Baudhuin, LM ;

Burgart, LJ ;

Leontovich, O ;

Thibodeau, SN .

FAMILIAL CANCER, 2005, 4 (03) :255-265

← 1 2 3 4 5 6 7 8 →